Our top pick for
Aviva plc is an insurance-diversified business based in the US. Aviva shares (AVVIY) are listed on the PINK and all prices are listed in US Dollars. Aviva employs 31,181 staff and has a market cap (total outstanding shares value) of USD$20.7 billion.
|52-week range||USD$4.1099 - USD$10.62|
|50-day moving average||USD$9.5344|
|200-day moving average||USD$8.3185|
|Wall St. target price||N/A|
|Dividend yield||USD$0.373 (3.54%)|
|Earnings per share (TTM)||USD$0.734|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Valuing Aviva stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aviva's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aviva's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Aviva shares trade at around 14x recent earnings.
Aviva's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9101. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Aviva's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||USD$13.9 billion|
|Return on assets TTM||0.45%|
|Return on equity TTM||12.2%|
|Market capitalisation||USD$20.7 billion|
TTM: trailing 12 months
There are currently 433,923 Aviva shares held short by investors – that's known as Aviva's "short interest". This figure is 2.1% down from 443,420 last month.
There are a few different ways that this level of interest in shorting Aviva shares can be evaluated.
Aviva's "short interest ratio" (SIR) is the quantity of Aviva shares currently shorted divided by the average quantity of Aviva shares traded daily (recently around 289282). Aviva's SIR currently stands at 1.5. In other words for every 100,000 Aviva shares traded daily on the market, roughly 1500 shares are currently held short.
However Aviva's short interest can also be evaluated against the total number of Aviva shares, or, against the total number of tradable Aviva shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aviva's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Aviva shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Aviva shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aviva.
Find out more about how you can short Aviva stock.
Dividend payout ratio: 736.2% of net profits
Recently Aviva has paid out, on average, around 736.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.27% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Aviva shareholders could enjoy a 3.27% return on their shares, in the form of dividend payments. In Aviva's case, that would currently equate to about $0.373 per share.
Aviva's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Aviva's most recent dividend payout was on 27 January 2021. The latest dividend was paid out to all shareholders who bought their shares by 10 December 2020 (the "ex-dividend date").
Over the last 12 months, Aviva's shares have ranged in value from as little as $4.1099 up to $10.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Aviva's is 1.2436. This would suggest that Aviva's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Aviva plc provides various insurance and savings products primarily in the United Kingdom, rest of Europe, North America, and South-East Asia. The company offers life insurance, long term health and accident insurance, savings, pension, and annuity products, as well as pension fund business and lifetime mortgage products. It also provides insurance cover to individuals, small and medium-sized businesses for risks associated primarily with motor vehicles and medical expenses, as well as property and liability, such as employers' and professional indemnity liabilities. In addition, the company offers personal and commercial lines insurance products; long-term insurance and savings products, primarily for individuals. Further, it provides investment management services for institutional pension fund mandates; and manages various retail investment products, including investment funds, unit trusts, open-ended investment companies, and individual savings accounts for third-party financial institutions, pension funds, public sector organizations, investment professionals, and private investors. Additionally, the company offers asset management, retirement, and protection insurance products. The company markets its products through a network of insurance brokers, as well as MyAviva platform. The company was formerly known as CGNU plc and changed its name to Aviva plc in July 2002. Aviva plc was founded in 1696 and is headquartered in London, the United Kingdom.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.